Pallas Capital Advisors LLC lifted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 4.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,481 shares of the biotechnology company’s stock after buying an additional 252 shares during the period. Pallas Capital Advisors LLC’s holdings in Blueprint Medicines were worth $622,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Strs Ohio boosted its holdings in shares of Blueprint Medicines by 94.3% in the fourth quarter. Strs Ohio now owns 6,800 shares of the biotechnology company’s stock valued at $627,000 after purchasing an additional 3,300 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Blueprint Medicines by 10.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,369 shares of the biotechnology company’s stock valued at $1,233,000 after acquiring an additional 1,314 shares in the last quarter. Federated Hermes Inc. purchased a new position in shares of Blueprint Medicines in the 4th quarter valued at $2,218,000. Xponance Inc. bought a new position in shares of Blueprint Medicines in the 4th quarter worth $378,000. Finally, Semanteon Capital Management LP purchased a new stake in shares of Blueprint Medicines during the 4th quarter worth $1,177,000.
Insider Activity at Blueprint Medicines
In other news, insider L. Becker Hewes sold 4,922 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $106.43, for a total transaction of $523,848.46. Following the transaction, the insider now directly owns 31,938 shares in the company, valued at approximately $3,399,161.34. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Blueprint Medicines news, insider L. Becker Hewes sold 4,922 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $106.43, for a total value of $523,848.46. Following the transaction, the insider now directly owns 31,938 shares in the company, valued at approximately $3,399,161.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Philina Lee sold 41,913 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51. The disclosure for this sale can be found here. In the last ninety days, insiders sold 171,977 shares of company stock valued at $17,622,599. 4.21% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on Blueprint Medicines
Blueprint Medicines Price Performance
Shares of NASDAQ BPMC traded up $0.76 during trading on Wednesday, hitting $93.96. The company had a trading volume of 72,748 shares, compared to its average volume of 718,865. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $121.90. The company has a quick ratio of 3.61, a current ratio of 3.76 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $106.20 and a two-hundred day simple moving average of $98.31. The firm has a market capitalization of $5.88 billion, a price-to-earnings ratio of -19.74 and a beta of 0.63.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.49. The company had revenue of $138.20 million during the quarter, compared to analyst estimates of $104.02 million. Blueprint Medicines had a negative return on equity of 176.65% and a negative net margin of 56.64%. Blueprint Medicines’s quarterly revenue was up 139.9% on a year-over-year basis. During the same period in the previous year, the business earned ($2.19) EPS. On average, research analysts expect that Blueprint Medicines Co. will post -4.67 earnings per share for the current year.
Blueprint Medicines Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Articles
- Five stocks we like better than Blueprint Medicines
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Stock Average Calculator
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- How to buy stock: A step-by-step guide for beginners
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMC – Free Report).
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.